Glaxo Wellcome clinical trials

Acquired by GlaxoSmithKline, Dec 27, 2000 · source ↗

The registry lists 72 studies whose lead sponsor is Glaxo Wellcome. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 29, 2008.

• 72studies on the registry
• 0open to participants now

Studies

Recruiting first, then most recently updated. Showing 50 of 72. List all 72 → · All GlaxoSmithKline studies →

• The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected PatientsCompletedNCT00002404Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the PastCompletedNCT00002320Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected PatientsCompletedNCT00002373Phase 1

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARCCompletedNCT00002020Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Treatment IND for 566C80 Therapy of Pneumocystis Carinii PneumoniaCompletedNCT00001991Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 DrugsCompletedNCT00002391Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARCCompletedNCT00002046Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-SulfadiazineCompletedNCT00001994Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)CompletedNCT00002026Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)CompletedNCT00002048Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMXCompletedNCT00002340Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00002440Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular DiseasesCompletedNCT00002044Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus DiseaseCompletedNCT00002001Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00002389Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia ComplexCompletedNCT00002163Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Safety and Effectiveness of 524W91CompletedNCT00002335Phase 1

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)CompletedNCT00002063Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV TreatmentCompletedNCT00002216Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / SulfamethoxazoleCompletedNCT00001996Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive PatientsCompletedNCT00002286Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV InfectionCompletedNCT00002086Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)Status unknownNCT00004981Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of 141W94 in Combination With Other Anti-HIV DrugsCompletedNCT00002372Phase 1

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected PatientsCompletedNCT00002195Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2CompletedNCT00002023Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Amprenavir in Patients With Protease Inhibitor-Related ComplicationsCompletedNCT00002417Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received TreatmentStatus unknownNCT00005017Phase 4

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV DrugsCompletedNCT00002217Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Safety and Effectiveness of a Combination Anti-HIV Drug TreatmentCompletedNCT00005018Phase 4

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected PatientsStatus unknownNCT00005663Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease InhibitorsCompletedNCT00002213Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected PatientsCompletedNCT00005106Phase 4

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Two Anti-HIV Drug CombinationsCompletedNCT00002203Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• 3TC (Lamivudine; GR109714X) Open-Label ProgramCompletedNCT00002108Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)CompletedNCT00002014Phase 1

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirCompletedNCT00002423Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV DrugsCompletedNCT00002442Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZTCompletedNCT00002436Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3CompletedNCT00002106Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected PatientsCompletedNCT00002000Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of 1592U89 in HIV-Infected AdultsCompletedNCT00002200Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV DrugsCompletedNCT00004852Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.CompletedNCT00002199Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive PatientsCompletedNCT00005764Phase 4

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Comparison of 141W94 and Indinavir in HIV-Infected PatientsCompletedNCT00002202Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected PatientsCompletedNCT00002390Phase 2

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow TransplantCompletedNCT00002284Not applicable

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune SystemsCompletedNCT00002315Phase 3

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline

• A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected AdultsCompletedNCT00004585Phase 4

  Sponsor listed in the registry: Glaxo Wellcome · First submitted before Glaxo Wellcome became part of GlaxoSmithKline